Navigation Links
Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share
Date:11/22/2011

eptor agonist, is a novel, first in class, small molecule, orally bioavailable drug with a proven efficacy in Phase 2 clinical studies and an excellent safety profile. CF101 is currently developed for ophthalmic indications. including dry eye syndrome (Phase 3), glaucoma (Phase 2) and Uveitis. CF101 is also developed for the treatment of autoimmune inflammatory diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3).

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd is a public company, trading on the Tel Aviv Stock Exchange (TASE: CFBI). Can-Fite was founded in 2000 by Prof Pnina Fishman, researcher in the Rabin Medical Center, and Dr. Ilan Cohen, patent attorney and senior partner at Reinhold Cohen Patent Attorneys, on the basis of Prof Fishman's scientific findings, and is focused on the development of small molecule drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. Can-Fite's lead drug, CF101, is in advanced clinical development for the treatment of autoimmune, inflammatory and ophthalmic diseases.  Can-Fite's second drug, CF102, is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience which includes over 700 patients who have participated in clinical trials conducted by it.

About Denali Concrete Management Inc.

Denali Concrete Management Inc. (OTCBB: DCMG) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. Denali's product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

This release contains forward-looking statements regarding Denali Concrete Management, Inc.'s future plans and expected performance based on assumptions the Company believes to be reasonable. &#
'/>"/>

SOURCE Denali Concrete Management Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. Cellectar Expands Clinical Management Team
7. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
8. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
9. Lilly Receives NCQA Design Certification for Depression Care Management Program
10. Micromet Announces Changes in Management Team
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEWPORT BEACH, Calif. , Sept. 30, 2014 ... prestigious accreditation of the American Association of Tissue ... Russell Cook , Chief Executive Officer. ... on-site inspection by a specially trained AATB inspector.  ... and administrative performance within the facility meets or ...
(Date:9/30/2014)... -- Georgia-Pacific Professional is a leading provider of hygienic ... range of away from home applications. Building on ... including hospitals, long-term care facilities, surgical centers and ... products and solutions to the dental community. ... control in the dental office," said Sean ...
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, ... America , has launched FluFree.com, a website designed ... vaccinations. For 20 years, Passport Health has ... the flu. The launch of FluFree.com is designed to ... and the number of people who actually chose to ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3
... CAMBRIDGE, Mass. Dec. 10 The US Army, through the ... Technologies a contract to develop a robotic approach to airway ... clearing a patient,s airway and inserting a tube to maintain ... intubation, is critical as the loss of proper air circulation ...
... , TITUSVILLE, N.J., Dec. 10 Treatment with once-monthly ... CONSTA®, according to new data from a comparative study of ... clinical trial were released this week. , An estimated one ... brain disorder that impairs a person,s ability to think clearly, ...
Cached Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10
(Date:9/30/2014)... unusual character from a "Seinfeld" episode or a John ... called SCID, short for severe combined immunodeficiency, forces patients ... their bodies, natural defenses are too weak to fight ... new births each year worldwide, SCID is a cousin ... immunodeficiency virus HIV/AIDS. , Now, using a mouse ...
(Date:9/30/2014)... Researchers report that some stickleback fish fathers can have ... most attentive fish dads cause their offspring to behave ... predators. These behavioral changes are accompanied by changes in ... appear in the Proceedings of the Royal ... of evidence that moms are very important for their ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... Carolina (PRWEB) September 30, 2014 ... and IT Infrastructure analytics across data center, cloud ... has achieved an important milestone of helping more ... plan for important projects such as IT infrastructure ... , The strong customer engagement rates and ...
(Date:9/30/2014)... September 30, 2014 A market research ... intelligence agency states that the global medical imaging reagents ... 18.5 billion by the end of 2019. The worldwide ... 10.3 billion in 2012, will report a compounded annual ... 18.5 billion worth market by 2019. , Browse the ...
Breaking Medicine News(10 mins):Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 2Health News:Virginia Tech researchers discover potential biomarker to detect 'bubble boy' disorder 3Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:Americans undergo colonoscopies too often, study finds 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3
... ... provide alternative natural relief prior to considering drugs. , ... St. Louis, MO (PRWEB) December 17, 2009 -- ... and flaking associated with severe skin conditions . Developed by Astrel Genome ...
... ... measures and outcomes reporting to monitor the impact of expected health improvements as it ... the contract. , ... Jacksonville, FL (PRWEB) December 17, 2009 -- HealthScreen Disease Management, an independent ...
... ... tub company helps raise money for kids battling severe illness and acute injury ... Salt Lake City, ... donation of a Bullfrog Spa to aid in fund raising efforts for Primary Children’s ...
... AUSTIN, Texas, Dec. 16 Austin,s Custom Tops , a ... Gray and Hill Country Home Health, a slider-eating throwdown at the ... up to cheer on the two brave contestants who ate their ... The Austin Children,s Shelter. , What started as a casual ...
... , CHEVY CHASE, Md., Dec. 16 ... capital firm, today announced that one of its portfolio ... to be acquired by Ethicon, Inc., a Johnson & ... million (net of estimated cash on hand at time ...
... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... today announced that Paul D. Mintz, M.D. has been appointed ... 1, 2010. , Dr. Mintz has been involved in ... He is a tenured Professor of Pathology and Medicine at ...
Cached Medicine News:Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Immucor Appoints New Board Director 2
Cannulated Interference Screws...
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
... moisturizing mist for the eyes developed with ... from Oregon Health Sciences University's Casey Eye ... (2000) and dry eye patients showed, on ... volume of the eyes' tear film without ...
... array with 275 channels gives ... just 2.2 cm. This ... when using advanced analysis techniques, ... (SAM) or minimum norm methods. ...
Medicine Products: